Profile data is unavailable for this security.
About the company
Apogee Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is advancing novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. APG777, the Company’s most advanced program, is being initially developed for the treatment of AD. With four validated targets in its portfolio, it is seeking to achieve efficacy and dosing through monotherapies and combinations of its novel antibodies. Its most advanced programs are APG777, APG990, APG333, and APG808. APG990 is an SQ extended half-life mAb that utilizes advanced antibody engineering to target OX40L. APG333 is a fully human mAb against thymic stromal lymphopoietin (TSLP). APG808 is an SQ extended half-life mAb targeting IL-4Rα. APG279 is for the dual inhibition of OX40L and IL-13.
- Revenue in USD (TTM)0.00
- Net income in USD-253.67m
- Incorporated2023
- Employees196.00
- LocationApogee Therapeutics Inc221 Crescent St.Building 17, Suite 102bWALTHAM 02453United StatesUSA
- Phone+1 (650) 394-5230
- Fax+1 (302) 655-5049
- Websitehttps://apogeetherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Viking Therapeutics Inc | 0.00 | -359.64m | 3.85bn | 53.00 | -- | 5.99 | -- | -- | -3.18 | -3.18 | 0.00 | 5.57 | 0.00 | -- | -- | 0.00 | -44.29 | -31.71 | -47.32 | -33.62 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -227.05 | -- | -- | -- |
| ACADIA Pharmaceuticals Inc | 1.07bn | 391.00m | 3.89bn | 796.00 | 10.00 | 3.17 | 9.66 | 3.63 | 2.28 | 2.28 | 6.31 | 7.21 | 0.7787 | 3.14 | 9.73 | 1,346,112.00 | 28.42 | 3.92 | 37.60 | 5.17 | 91.69 | 93.59 | 36.49 | 4.59 | 3.71 | -- | 0.00 | 0.00 | 11.87 | 19.39 | 72.66 | -- | 68.65 | -- |
| Gyroscope Therapeutics Holdings Ltd(ADR) | -100.00bn | -100.00bn | 4.02bn | 167.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -70.87 | -- | -58.56 | -- | -- | -- |
| Crinetics Pharmaceuticals Inc | 7.70m | -465.32m | 4.26bn | 594.00 | -- | 3.92 | -- | 553.46 | -4.94 | -4.94 | 0.0818 | 10.38 | 0.006 | -- | 1.71 | 12,956.23 | -36.34 | -36.26 | -38.52 | -38.45 | 66.07 | -- | -6,046.22 | -6,696.84 | 12.30 | -- | 0.00 | -- | 640.71 | 155.27 | -55.93 | -- | 98.71 | -- |
| Scholar Rock Holding Corp | 0.00 | -353.43m | 4.44bn | 196.00 | -- | 17.60 | -- | -- | -3.15 | -3.15 | 0.00 | 2.47 | 0.00 | -- | -- | 0.00 | -119.63 | -45.06 | -144.40 | -51.62 | -- | -- | -- | -1,134.62 | -- | -- | 0.2891 | -- | -- | -- | -48.56 | -- | -49.93 | -- |
| Structure Therapeutics Inc (ADR) | 0.00 | -141.20m | 4.46bn | 220.00 | -- | 2.94 | -- | -- | -2.49 | -2.49 | 0.00 | 21.41 | 0.00 | -- | -- | 0.00 | -11.35 | -18.40 | -11.83 | -19.33 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -15.24 | -- | 185.66 | -- |
| Terns Pharmaceuticals Inc | 0.00 | -94.44m | 4.46bn | 59.00 | -- | 12.95 | -- | -- | -1.03 | -1.03 | 0.00 | 3.25 | 0.00 | -- | -- | 0.00 | -27.78 | -32.69 | -28.92 | -35.03 | -- | -- | -- | -33,013.70 | -- | -- | 0.00 | -- | -- | -- | 1.50 | -- | -45.82 | -- |
| Erasca Inc | 0.00 | -127.69m | 4.50bn | 103.00 | -- | 11.85 | -- | -- | -0.4506 | -0.4506 | 0.00 | 1.23 | 0.00 | -- | -- | 0.00 | -26.90 | -41.53 | -28.68 | -44.78 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -29.28 | -- | -36.84 | -- |
| Amicus Therapeutics, Inc. | 634.21m | -27.11m | 4.51bn | 511.00 | -- | 16.28 | -- | 7.11 | -0.0885 | -0.0885 | 2.05 | 0.8822 | 0.7311 | 0.4196 | 5.86 | 1,241,116.00 | -3.13 | -17.56 | -4.02 | -21.71 | 88.50 | 89.24 | -4.27 | -32.86 | 1.88 | 0.8051 | 0.5888 | -- | 20.05 | 19.44 | 51.68 | -- | 0.424 | -- |
| Apogee Therapeutics Inc | 0.00 | -253.67m | 4.84bn | 196.00 | -- | 7.17 | -- | -- | -4.36 | -4.36 | 0.00 | 9.89 | 0.00 | -- | -- | 0.00 | -36.18 | -- | -37.98 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -116.88 | -- | -- | -- |
| CG Oncology Inc | 2.17m | -151.48m | 4.88bn | 113.00 | -- | 6.58 | -- | 2,243.32 | -2.03 | -2.03 | 0.0292 | 8.78 | 0.0034 | -- | 6.67 | 19,238.94 | -23.63 | -- | -24.51 | -- | 4.09 | -- | -6,967.99 | -- | 22.74 | -- | 0.0043 | -- | 458.33 | -- | -29.85 | -- | -- | -- |
| Celcuity Inc | 0.00 | -162.72m | 5.01bn | 87.00 | -- | 40.07 | -- | -- | -3.67 | -3.67 | 0.00 | 2.70 | 0.00 | -- | -- | 0.00 | -43.45 | -42.61 | -47.58 | -45.75 | -- | -- | -- | -- | -- | -48.30 | 0.7325 | -- | -- | -- | -75.26 | -- | -8.05 | -- |
| Alkermes Plc | 1.48bn | 241.66m | 5.04bn | 2.05k | 21.12 | 2.75 | 18.47 | 3.42 | 1.43 | 1.43 | 8.74 | 10.99 | 0.6498 | 1.04 | 4.08 | 719,950.80 | 10.64 | 10.11 | 13.68 | 13.22 | 86.69 | 84.10 | 16.37 | 15.06 | 3.19 | -- | 0.00 | 0.00 | -5.25 | 7.28 | -35.06 | -- | -0.8671 | -- |
| Immunovant Inc | 0.00 | -464.20m | 5.65bn | 362.00 | -- | 5.72 | -- | -- | -2.68 | -2.68 | 0.00 | 4.85 | 0.00 | -- | -- | 0.00 | -63.01 | -47.00 | -69.35 | -51.13 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -59.58 | -- | 89.57 | -- |
Data as of Mar 03 2026. Currency figures normalised to Apogee Therapeutics Inc's reporting currency: US Dollar USD
58.18%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 31 Dec 2025 | 8.15m | 14.87% |
| Wellington Management Co. LLPas of 31 Dec 2025 | 4.57m | 8.33% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 3.01m | 5.49% |
| T. Rowe Price Investment Management, Inc.as of 31 Dec 2025 | 2.73m | 4.98% |
| RTW Investments LPas of 31 Dec 2025 | 2.71m | 4.95% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 2.48m | 4.53% |
| Perceptive Advisors LLCas of 31 Dec 2025 | 2.33m | 4.25% |
| Driehaus Capital Management LLCas of 31 Dec 2025 | 2.18m | 3.98% |
| Janus Henderson Investors US LLCas of 31 Dec 2025 | 2.04m | 3.72% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 1.69m | 3.08% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
